A signing ceremony at Abela Qatar International headquarters, on August 17, has brought together Rwanda Medical Supply (RMS), Labophar Ltd, and Philex Pharmaceuticals to formalise two agreements, a statement from the Embassy of Rwanda to Qatar said Tuesday.
The first agreement established a Local Technical Representative (LTR) partnership between RMS and Philex. Signed by RMS deputy CEO Diana Mutoni, and Philex CEO and partner Wassem Hamad, this partnership positions RMS as Philex’s official representative in Rwanda.
Through the agreement, RMS will ensure full regulatory compliance and facilitate the import and nationwide distribution of essential medical commodities, including oncology and cardiology medicines, as well as other specialized supplies, across all 30 districts of Rwanda.
In parallel, a joint venture and technology transfer agreement was signed between Labophar Ltd and Philex to localise the production of Philex’s solid dosage forms in Rwanda. This agreement was signed by Labophar CEO Pascal Gatete, and Philex's Hamad, marking an important step toward enhancing Rwanda’s pharmaceutical manufacturing capacity and reducing reliance on imports.
Both agreements were signed in the presence of the Ambassador of Rwanda to Qatar, Igor Marara, alongside other guests and stakeholders. "These agreements reinforce Rwanda’s commitment to advancing healthcare delivery through both stronger supply chain systems and local production of essential medicines. They also highlight the growing partnership between Rwanda and Qatar, underscoring both countries’ shared vision of fostering innovation, resilience, and well-being for their people," the statement added.
